BidaskClub upgraded shares of Cambrex Corporation (NYSE:CBM) from a hold rating to a buy rating in a research note published on Friday.

A number of other brokerages have also recently issued reports on CBM. Zacks Investment Research upgraded Cambrex Corporation from a hold rating to a buy rating and set a $59.00 price objective on the stock in a research note on Thursday, May 11th. ValuEngine cut Cambrex Corporation from a buy rating to a hold rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $64.00.

Shares of Cambrex Corporation (CBM) traded down 2.14% during midday trading on Friday, hitting $57.25. 284,703 shares of the stock traded hands. Cambrex Corporation has a 12-month low of $38.30 and a 12-month high of $62.95. The firm’s 50 day moving average price is $58.97 and its 200 day moving average price is $55.37. The company has a market capitalization of $1.86 billion, a PE ratio of 21.79 and a beta of 2.28.

Cambrex Corporation (NYSE:CBM) last announced its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company had revenue of $134.55 million for the quarter, compared to analysts’ expectations of $136.82 million. During the same quarter in the prior year, the business posted $0.68 EPS. The business’s revenue was up 13.4% compared to the same quarter last year. Analysts expect that Cambrex Corporation will post $3.04 EPS for the current year.

WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/cambrex-corporation-nysecbm-lifted-to-buy-at-bidaskclub.html.

In related news, VP Samantha Hanley sold 14,000 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $57.56, for a total value of $805,840.00. Following the sale, the vice president now owns 1,500 shares in the company, valued at approximately $86,340. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total value of $650,280.00. Following the completion of the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $5,165,824.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,656 shares of company stock worth $4,064,423. 2.48% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC boosted its stake in Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares during the period. Creative Planning boosted its stake in Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares during the period. Flinton Capital Management LLC boosted its stake in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares during the period. YorkBridge Wealth Partners LLC boosted its stake in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares during the period. Finally, Meeder Asset Management Inc. acquired a new stake in Cambrex Corporation during the first quarter worth $109,000. Institutional investors and hedge funds own 98.28% of the company’s stock.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.